Menu
Not yet recruiting NCT07489560

Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns

Phase IV Interventional Partial Thickness Burn

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Amnion-Intermediate-Chorion, Standard of Care (SOC).
Who it may be relevant to
Registry conditions: Partial Thickness Burn. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Prospective, Multicenter, Randomized, Controlled Clinical Investigation Evaluating the Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft vs Standard of Care in the Treatment of Partial Thickness Thermal Burns

Overview

This study will evaluate the efficacy of a dehydrated human placental tissue product, commercially labeled as AmCoreMatrix Burn ™ versus SOC in the closure of partial thickness burns. Human Cellular and Tissue based Products (HCT/Ps), specifically Dehydrated Human Amnion - Intermediate Layer - Chorion Membrane (dHAICM) offer a multimodal biological approach to burn management. Unlike synthetic dressings or silver-based creams, dHAICM serves as a sophisticated bioactive scaffold. It is a minimally manipulated allograft that provides superior tensile strength and barrier function compared to single-layer membranes. This study aims to document its performance in hospital burn units.

Interventions

  • Other Amnion-Intermediate-Chorion
    Dehydrated human placental multilayer allograft derived from donated human tissue. AIC contains amnion and chorion layers as well as basement membrane and trophoblast.
  • Procedure Standard of Care (SOC)
    Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.

Primary outcome measures

  • Time to Complete Epithelialization [Time frame: 1-10 weeks]
Secondary outcome measures (5)
  • Percentage of Burn Area Change [Time frame: 1-10 weeks]
  • Frequency of Full Epithelialization [Time frame: 1-10 weeks]
  • Changes in Pain Scores Associated with Target Burns [Time frame: 1-10 weeks]
  • Changes in Scarring Quality of Target Burn [Time frame: 1-10 weeks]
  • Incidents of Adverse Events [Time frame: 1-10 weeks]

Eligibility criteria

Inclusion criteria

  • 18 years of age or older
  • One or more thermal burns classified as either superficial partial thickness or deep partial thickness.
  • Total Body Surface Area (TBSA) involvement between 5% and 15%.
  • Total burn index wound area is greater than 25 cm 2 and less than 0.25 m 2 (2500 cm 2 )
  • 1 If 2 or more burns are present, each must have an area greater than 15 cm 2
  • The participant must be willing and able to participate in the informed consent process.

Exclusion criteria

  • Full thickness burns.
  • Burns present for \>72 hours prior to study evaluation
  • Burns requiring immediate autografting.
  • Superficial burns (1 st -degree) or burns not meeting criteria to be included in TBSA calculations.
  • Chemical or electrical burns.
  • Burns secondary to blast injury.
  • Burns causing vascular or respiratory compromise and burns requiring escharotomy
  • Any severe systemic comorbidities which could impair healing (e.g. active sepsis or major organ failure).
  • Known coagulopathy, platelet disorder, INR \> 1.6, PTT \> 38s, or platelets \< 50,000 per mm 3
  • Uncontrolled diabetes.
  • Known life expectancy of \< 6 months.
  • Evidence of active infection in burn.
  • Target area for treatment includes the head, neck, palms of hands, soles of the feet, or genitals.
  • Viral infection which could impair healing or immune function (e.g. HIV, HBV, HCV)
  • Participants of childbearing potential who are pregnant, considering becoming pregnant within the next 6 months, and/or are unwilling to utilize an appropriate form of contraception.
  • Currently requiring dialysis or planning to start within 6 months.
  • Medical or psychological condition that, in the opinion of the investigator, may interfere with study assessments.
  • Treated with hyperbaric oxygen therapy or a skin substitute within the 30 days prior to screening visit.
  • Sensitivity to ofloxacin, vancomycin, or amphotericin antibiotics.
  • Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07489560 · CELLBIO-2026-002

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗